Generex Biotechnology Newswire

Generex Biotechnology Newswire

Comprehensive Real-Time News Feed for Generex Biotechnology.

Results 1 - 20 of 31 in Generex Biotechnology

  1. Generex Biotechnology Corporation Announces New Clinical Trial Of...Read the original story

    Sep 19, 2017 | BioSpace

    Generex Biotechnology Corporation today announced the participation by its subsidiary, Hema Diagnostic Systems LLC , in a diagnostic clinical trial for tuberculosis in Sub-Saharan African countries. The trial is being conducted by a number of international collaborating institutions and the results of the trial will determine the accuracy and clinical utility of the Rapid 1-2-3 A Hema Tuberculosis EXPRESS A TB-XT and the Rapid 1-2-3 A Hema Tuberculosis EXPRESS A TB-XT3 point-of-care tests as primary triage assays for the presence of active tuberculosis, or as part of a combination of tests used for that purpose.

    Comment?

  2. Limited Growth Opportunities Likely to Curb Sublingual Sprays Market Growth over 2025Read the original story w/Photo

    Sep 12, 2017 | SBWire

    ... Therapeutics, Ltd., Sun Pharmaceutical Industries Ltd., Mist Pharmaceuticals., NovaDel Pharma Inc., Generex Biotechnology Corp., GW Pharmaceuticals, plc., Europlaz Technologies and Piramal Enterprises Ltd. About Persistence Market Research ...

    Comment?

  3. Sublingual Sprays Market Projected to Gain Significant Value by 2025Read the original story w/Photo

    Sep 11, 2017 | SBWire

    ... Therapeutics, Ltd., Sun Pharmaceutical Industries Ltd., Mist Pharmaceuticals., NovaDel Pharma Inc., Generex Biotechnology Corp., GW Pharmaceuticals, plc., Europlaz Technologies and Piramal Enterprises Ltd. About Persistence Market Research ...

    Comment?

  4. Sublingual Sprays Market for the Forecast 2017 - 2025Read the original story w/Photo

    Aug 30, 2017 | SBWire

    ... Therapeutics, Ltd., Sun Pharmaceutical Industries Ltd., Mist Pharmaceuticals., NovaDel Pharma Inc., Generex Biotechnology Corp., GW Pharmaceuticals, plc., Europlaz Technologies and Piramal Enterprises Ltd. About Persistence Market Research (PMR) ...

    Comment?

  5. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Aug 7, 2017 | Business Wire

    ... structured credit strategies, today announced that John DiRocco has joined the firm as Chief ... )--Generex Biotechnology Corporation (www.generex.com) (OTCPink:GNBT) today provided the following summary of the Ii-Key Hybrid Vaccine Platform under ...

    Comment?

  6. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Aug 7, 2017 | Business Wire

    ... structured credit strategies, today announced that John DiRocco has joined the firm as Chief ... )--Generex Biotechnology Corporation (www.generex.com) (OTCPink:GNBT) today provided the following summary of the Ii-Key Hybrid Vaccine Platform under ...

    Comment?

  7. Generex Provides Summary of Ii-Key Hybrid Vaccine PlatformRead the original story w/Photo

    Aug 7, 2017 | Business Wire

    )--Generex Biotechnology Corporation ( www.generex.com ) (OTCPink:GNBT) today provided the following summary of the Ii-Key Hybrid Vaccine Platform under development by its wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ). ...

    Comment?

  8. Generex Biotechnology Corporation Announces Collaboration With Merck...Read the original story

    Jul 30, 2017 | BioSpace

    Generex Biotechnology Corporation today announced that its wholly-owned subsidiary, Antigen Express, Inc. has entered into a clinical trial collaboration agreement with Merck , through a wholly-owned subsidiary, to evaluate Antigen's AE37 cancer vaccine in combination with Merck's anti-PD-1 therapy, KEYTRUDA A , in patients with metastatic triple-negative breast cancer. The study will evaluate preliminary safety and efficacy of the combination in a Phase II trial.

    Comment?

  9. Send Press Releases with GlobeNewswireRead the original story

    Jun 20, 2017 | GlobeNewswire

    Generex Biotechnology Receives Approval From the Ministry of Health of the United Arab Emirates to Sell Generex Oral-Lyn to Prominent Diabetes Centre in the Middle East Region DIAMYD ANNUAL MEETING: BOARD OF DIRECTORS ELECTED. NEW CEO TO BE PRESENTED SHORTLY.

    Comment?

  10. Therapy Focus - Not Quite The Hammer For Sickle Cell DiseaseRead the original story w/Photo

    May 26, 2017 | Seeking Alpha

    When it comes to serious diseases with virtually no treatments the US FDA has shown flexibility in approving new therapies, even if these have questionable efficacy. This could play out again when the agency decides on The case of Endari is curious for several reasons, not least the fact that it has a cheaply available active ingredient and a data package flattered by statistical changes; its maker until recently looked like being taken over by the struggling Generex .

    Comment?

  11. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Mar 29, 2017 | Business Wire

    ... agenda for the supply chain conference of the year - JDA FOCUS 2017 - JDA's annual global custo... )--Generex Biotechnology Corporation (OTC Pink:GNBTD) today announced that it has entered into a securities purchase agreement with an institutional ...

    Comment?

  12. Generex Biotechnology Corporation Announces $115M Convertible...Read the original story

    Mar 28, 2017 | BioSpace

    Generex Biotechnology Corporation today announced that it has entered into a securities purchase agreement with an institutional investor pursuant to which such investor has agreed to purchase in a private placement in multiple tranches 109,000 shares of the Company's newly designed Series H Convertible Preferred Stock and 6,000 shares of the Company's newly designed Series I Convertible Preferred Stock for an aggregate purchase price of $115,000,000 . The Preferred Stock is convertible into shares of the Company's common stock at a conversion price of $2.50 per share .

    Comment?

  13. Generex Biotechnology Corporation Announces Featured Presentation Of...Read the original story

    Mar 26, 2017 | BioSpace

    Generex Biotechnology Corporation today announced that Dr. Eric von Hofe, Ph.D., President of the Company's wholly-owned immuno-therapeutics subsidiary, Antigen Express, Inc. , will be a featured speaker at the Cambridge Healthtech Institute's second annual Oligonucleotide & Peptide Therapeutics conference being held in Cambridge, MA March 27 - 29, 2017. "The low toxicity and high specificity of Antigen Express peptides make them particularly attractive for combination studies with checkpoint inhibitors.

    Comment?

  14. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Mar 14, 2017 | Business Wire

    ... research protocols in biology, has improved the accuracy of a delicate laboratory techni... )--Generex Biotechnology Corporation (OTCPink:GNBT) today announced a reverse stock split of its shares of common stock at a ratio of 1-for-1000. As of ...

    Comment?

  15. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Mar 14, 2017 | Business Wire

    ... research protocols in biology, has improved the accuracy of a delicate laboratory techni... )--Generex Biotechnology Corporation (OTCPink:GNBT) today announced a reverse stock split of its shares of common stock at a ratio of 1-for-1000. As of ...

    Comment?

  16. Generex Biotechnology Corporation Announces Reverse Stock SplitRead the original story

    Mar 13, 2017 | BioSpace

    MIRAMAR, Florida & TORONTO-- --Generex Biotechnology Corporation today announced a reverse stock split of its shares of common stock at a ratio of 1-for-1000. As of the open of the market on March 14, 2017, the Company's common stock will begin trading on a split-adjusted basis.

    Comment?

  17. Generex Biotechnology Corporation Provides Access Information For...Read the original story

    Feb 20, 2017 | BioSpace

    Generex Biotechnology Corporation today announced the following access information for its investor conference call, to be hosted by Joseph Moscato, Company President & Chief Executive Officer, and his management team, tomorrow, Wednesday, February 22, 2017 , at 10 am. Eastern time : The purpose of the conference call will be to provide investors with an update on the Company's initiatives and strategic plans.

    Comment?

  18. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Feb 21, 2017 | Business Wire

    ... and translation-related technologies, today announced that it has opened its newest locatio... )--Generex Biotechnology Corporation (OTCPink:GNBT) today announced the following access information for its investor conference call, to be hosted by ...

    Comment?

  19. Generex Provides Access Information for Investor Conference Call Scheduled for February 22, 2017Read the original story w/Photo

    Feb 21, 2017 | Business Wire

    )--Generex Biotechnology Corporation (OTCPink:GNBT) today announced the following access information for its investor conference call, to be hosted by Joseph Moscato, Company President & Chief Executive Officer, and his management team, tomorrow, ...

    Comment?

  20. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Feb 9, 2017 | Business Wire

    ... after demonstrating strong Environmental, Social and Governance (ESG) pra... )--On January 23, 2017 Generex Biotechnology Corporation (OTCPink:GNBT) announced a letter of intent for the acquisition of a controlling equity interest in E... )--Docker ...

    Comment?